Bragado, PalomaFernández-Nogueira, PatriciaCarbó Carbó, NeusGascón, Pere2021-03-302021-03-302020-12-081949-2553https://hdl.handle.net/2445/175915The majority of women with HER2-positive breast cancer will initially respond to trastuzumab and/or other HER2-targeted therapies such as pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1). However [...].3 p.application/pdfengcc-by (c) Bragado, Paloma et al., 2020http://creativecommons.org/licenses/by/3.0/esFibroblastsCàncerFibroblastsCancerinfo:eu-repo/semantics/article7105282021-03-30info:eu-repo/semantics/openAccess33346249